doctor
Careology specialises in connecting people with cancer, their families and healthcare providers through its data-driven platform.

Healthtech firm raises £1.12m to develop real-time cancer care platform

A healthtech firm specialising in cancer care has secured £1.12m in funding from private angel investors.

Careology, which specialises in connecting people with cancer, their families and healthcare providers through a data-driven platform, has secured the funding as well as making appointments to its board.

Founded by Paul Landau - who supported his wife through cancer - Careology uses technology to provide real-time care to those with cancer, aiming to provide a seamless experience for patients and their families.

This latest funding will be used to expand the Careology team, invest in its sales and marketing, and accelerate its technology roadmap following the product’s launch earlier this year.

Paul Landau, Careology founder and CEO, commented: “I am delighted to announce this funding round which will help us accelerate our launch plans, firmly establishing Careology in the market.

“Having supported my wife during her cancer journey over the last three years and experienced first-hand the daunting journey faced by patients and their family, I am hugely excited to be delivering a powerful technology platform that transforms cancer care - both during and beyond treatment.”

As part of the fundraise, the firm has made some key appointments to its board including healthtech entrepreneur Dr. Henry Carleton as chairman and Alan Marks - former NED of Receipt Bank - as investor director.

Henry Carleton explained: “We understand the real need for consumer-centric technology that better supports patients facing such a complex diagnosis.

“With Careology there is an enormous opportunity to transform the healthcare continuum and we will enable seamless connectivity and insight to clinicians responsible for patient care. Careology is well poised to become the leading global player in this nascent space.”

Alan Marks added: “I know I speak for the board and our investors when I say we are thrilled to be part of Careology’s goal of revolutionising cancer care.

“We’ve been tremendously impressed by the quality of Careology’s operations and the team, and are ready to help the company achieve its vast potential.”

Our Partners